Operator-Assisted Oscilla Audiometry as a Basis for Hearing Aid Fitting (The Oscilla Validation Study)
Validation of Operator-Assisted Oscilla Audiometry as a Diagnostic Tool and Basis for Hearing Aid Fitting in Adults With Uncomplicated Hearing Loss: A Blinded Non-Inferiority Randomised Controlled Trial
The purpose of this study is to find out whether hearing tests performed with the Oscilla A60 audiometer, where the patient largely tests themselves with minimal staff assistance, are accurate enough to be used for diagnosing hearing loss and as the sole basis for fitting hearing aids. Adults referred for their first hearing aids at Aalborg University Hospital will have their hearing tested both with the Oscilla audiometer and by a trained audiology assistant at the same visit. Participants are then randomly assigned to receive hearing aids fitted based on either the Oscilla hearing test or the audiology assistant's hearing test. The main questions are: (1) Do the Oscilla results agree with the audiology assistant's results for both air-conduction and bone-conduction hearing thresholds? (2) Do participants fitted based on the Oscilla test report a hearing benefit that is not worse than that of participants fitted based on the standard test, two months after fitting?
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Demand for audiometric testing in public hearing clinics is increasing due to population ageing. Operator-assisted automated audiometry may expand capacity, but its use as the sole basis for hearing aid prescription, and its accuracy for bone-conduction (BC) thresholds, has not been established. This single-site study at the Department of Audiology, Aalborg University Hospital (locations in Aalborg and Hobro) enrols 268 first-time hearing aid users with uncomplicated, symmetric sensorineural hearing loss.
At Visit 1, all participants undergo both Oscilla A60 audiometry (air conduction [AC] 250-8000 Hz; BC 250-4000 Hz) and standard manual audiometry by an audiology assistant (reference standard), in randomised order. Agreement between methods is assessed with Bland-Altman analysis against pre-specified acceptance criteria (95% CI of bias within ±5 dB; 95% limits of agreement within ±15 dB for AC and ±20 dB for BC). After confirmation of eligibility, participants are randomised 1:1, stratified by hearing loss severity (PTA-4 ≤45 vs >45 dB HL) and location, to hearing aid fitting based on the Oscilla audiogram or the audiology assistant audiogram. All participants are fitted bilaterally with BTE/RIC hearing aids to the NAL-NL2 target, verified with automated real-ear measurements (within ±5 dB). Volume control and app connectivity are disabled until the two-month follow-up. The primary patient-reported outcome is the change in SSQ12 total score from baseline to two months post-fitting, with a non-inferiority margin of -0.81 points. Secondary outcomes are IOI-HA, daily hearing aid use (data logging) and SSQ12 subscales. The study is a clinical investigation under Article 82 of Regulation (EU) 2017/745.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Lene D Siggaard, MD, PhD
- Número de teléfono: +45 20633492
- Correo electrónico: lene.dahl@rn.dk
Copia de seguridad de contactos de estudio
- Nombre: Camilla L Sørensen, Cand. med.
- Correo electrónico: c.lorents@rn.dk
Ubicaciones de estudio
-
-
-
Aalborg, Dinamarca, 9000
- Department of Audiology, Aalborg University Hospital
-
Contacto:
- Camilla L Sørensen, Cand. med.
- Correo electrónico: c.lorents@rn.dk
-
Contacto:
- Lene D Siggaard, MD, PhD
- Número de teléfono: +4520633492
- Correo electrónico: lene.dahl@rn.dk
-
Hobro, Dinamarca, 9500
- Hearing Clinic, Aalborg University Hospital
-
Contacto:
- Camilla L Sørensen, Cand. med.
- Correo electrónico: c.lorents@rn.dk
-
Contacto:
- Lene D Siggaard, MD, PhD
- Número de teléfono: +4520633492
- Correo electrónico: lene.dahl@rn.dk
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Adults (≥18 years) referred for first-time hearing aid fitting at the Department of Audiology, Aalborg University Hospital
- Uncomplicated sensorineural hearing loss as defined by the Danish national clinical guidelines
- Hearing thresholds exceeding 20 dB HL at two or more frequencies in the range 0.5-4 kHz
- Pure-tone average (PTA-4; 0.5, 1, 2, 4 kHz) ≥30 dB HL in the better ear
- Symmetric hearing loss (PTA-4 difference between ears ≤15 dB)
- Word discrimination score ≥25% (DANTALE I at PTA + 40 dB HL)
- Danish native speaker
- No prior hearing aid experience
- Able to complete questionnaires online or on paper
- Written informed consent
Exclusion Criteria:
- Air-conduction thresholds exceeding 80 dB HL at two or more frequencies
- Air-bone gap >15 dB at one or more frequencies below 1 kHz
- Fluctuating hearing loss (e.g., Ménière's disease) or ongoing ototoxic medication
- Ear surgery (ear canal, middle ear or inner ear) within the past 12 months
- Hearing loss classified as complicated according to national clinical guidelines
- Visual or motor impairment precluding independent use of the Oscilla system
- Candidates for in-the-ear hearing aids only (all participants are fitted with BTE or RIC hearing aids)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Diagnóstico
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Oscilla-based fitting
Hearing aids fitted bilaterally to NAL-NL2 targets based on the Oscilla A60 audiogram, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: Paired audiometry and Oscilla-based hearing aid fitting). |
At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order. Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the Oscilla A60 audiogram as the sole audiometric basis, verified with auto-REM (within ±5 dB of target). Other names: Oscilla A60 Diagnostic Audiometer. |
|
Comparador activo: Manual audiometry-based fitting
Hearing aids fitted bilaterally to NAL-NL2 targets based on the audiogram obtained by a qualified audiology assistant, verified with automated real-ear measurement. Volume control and app connectivity disabled for two months (linked interventions: paired audiometry and manual audiometry-based hearing aid fitting). |
At Visit 1, all participants undergo both operator-assisted Oscilla A60 audiometry (AudioConsole v4.6.0; AC and BC thresholds; operator places the BC headband only) in a quiet room (<50 dB SPL) and manual pure-tone audiometry (AC and BC, ISO 8253-1) by a qualified audiology assistant in a sound-attenuating booth, in randomised order. Bilateral BTE/RIC hearing aid fitting to NAL-NL2 targets using the audiology assistant audiogram, verified with auto-REM (within ±5 dB of target). Standard clinical practice. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Agreement between Oscilla A60 and manual audiometry for air-conduction thresholds
Periodo de tiempo: Visit 1 (Week 0)
|
Bland-Altman mean difference (Oscilla minus manual) and 95% limits of agreement in dB, plus mean absolute difference, at 0.5, 1, 2 and 4 kHz separately. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±15 dB. Both ears included, clustering handled with a mixed-effects model. |
Visit 1 (Week 0)
|
|
Agreement between Oscilla A60 and manual audiometry for bone-conduction thresholds
Periodo de tiempo: Visit 1 (Week 0)
|
As above for bone-conduction thresholds at 0.5, 1, 2 and 4 kHz. Agreement is acceptable if the 95% CI of the bias is within ±5 dB and the 95% limits of agreement are within ±20 dB. |
Visit 1 (Week 0)
|
|
Change in SSQ12 total score
Periodo de tiempo: Baseline (Week 0) and 2 months after hearing aid fitting
|
Speech, Spatial and Qualities of Hearing Scale, 12-item version; total score = mean of 12 items, range 0-10, higher = better. Non-inferiority if the lower bound of the two-sided 95% CI for the between-group difference in change (Oscilla minus control) is above -0.81 points. |
Baseline (Week 0) and 2 months after hearing aid fitting
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
IOI-HA total score
Periodo de tiempo: 2 months after hearing aid fitting
|
International Outcome Inventory for Hearing Aids, Danish version; 7 items scored 1-5, total range 7-35, higher = better outcome. Compared between groups |
2 months after hearing aid fitting
|
|
Daily hearing aid use
Periodo de tiempo: From hearing aid fitting to 2 months after fitting
|
Mean daily hearing aid usage time in hours/day from the hearing aid data log, compared between groups |
From hearing aid fitting to 2 months after fitting
|
|
Change in SSQ12 subscale scores
Periodo de tiempo: Baseline (Week 0) and 2 months after hearing aid fitting
|
Change in the speech, spatial and qualities subscale scores (each range 0-10, higher = better) |
Baseline (Week 0) and 2 months after hearing aid fitting
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Lene D Siggaard, MD, PhD, Department of Otolaryngology, Head- and Neck Surgery and Audiology, Aalborg University Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- F2026-115
- Regional Innovation Fund (Otro número de subvención/financiamiento: North Denmark Region)
- Danish Medicines Agency (Identificador de registro: 16-0302-225)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Pseudonymised individual participant data may be shared upon reasonable request after publication, subject to approval under the GDPR and Danish data protection law and a data processing agreement.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .